DK1350109T3 - Markör for betændelsestilstande - Google Patents

Markör for betændelsestilstande

Info

Publication number
DK1350109T3
DK1350109T3 DK02707438T DK02707438T DK1350109T3 DK 1350109 T3 DK1350109 T3 DK 1350109T3 DK 02707438 T DK02707438 T DK 02707438T DK 02707438 T DK02707438 T DK 02707438T DK 1350109 T3 DK1350109 T3 DK 1350109T3
Authority
DK
Denmark
Prior art keywords
marker
inflammatory conditions
pregnancy
plasma protein
acute coronary
Prior art date
Application number
DK02707438T
Other languages
English (en)
Inventor
Cheryl A Conover
Antonio Bayes-Genis
Jr David R Holmes
Robert S Schwartz
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of DK1350109T3 publication Critical patent/DK1350109T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02707438T 2001-01-12 2002-01-11 Markör for betændelsestilstande DK1350109T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/760,376 US6500630B2 (en) 2001-01-12 2001-01-12 Marker for inflammatory conditions
PCT/US2002/000762 WO2002056015A1 (en) 2001-01-12 2002-01-11 Marker for inflammatory conditions

Publications (1)

Publication Number Publication Date
DK1350109T3 true DK1350109T3 (da) 2009-08-31

Family

ID=25058918

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02707438T DK1350109T3 (da) 2001-01-12 2002-01-11 Markör for betændelsestilstande

Country Status (11)

Country Link
US (9) US6500630B2 (da)
EP (2) EP1350109B1 (da)
JP (3) JP4338972B2 (da)
AT (1) ATE431551T1 (da)
AU (1) AU2002241845B2 (da)
CA (1) CA2434512C (da)
DE (1) DE60232303D1 (da)
DK (1) DK1350109T3 (da)
ES (1) ES2324767T3 (da)
PT (1) PT1350109E (da)
WO (1) WO2002056015A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464121C (en) * 2000-10-20 2013-08-13 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
WO2004046722A2 (de) * 2002-11-16 2004-06-03 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
PT1882946E (pt) * 2003-12-23 2010-04-21 Roche Diagnostics Gmbh Método para avaliar artrite reumatóide através da medição de anti-ccp e interleucina 6
EP1709448B1 (en) * 2004-01-28 2008-10-22 Turun Yliopisto Improved method for diagnosing acute coronary syndrome
US7608458B2 (en) * 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
CA2554836A1 (en) * 2004-02-05 2005-08-25 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US20050287574A1 (en) * 2004-06-23 2005-12-29 Medtronic, Inc. Genetic diagnostic method for SCD risk stratification
US8027791B2 (en) * 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US8335652B2 (en) * 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
JP2008545139A (ja) * 2005-06-29 2008-12-11 ルールズ−ベースド メディスン，インコーポレーテッド 急性冠症候群の診断方法及び診断キット
NZ568992A (en) 2005-11-17 2012-01-12 Biogen Idec Inc Platelet aggregation assays comprising platelet activiating agents and agents that cross-links the CD40L-binding moiety
US20100310461A1 (en) * 2007-04-18 2010-12-09 Biochromix Pharma Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US20100310462A1 (en) * 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
ATE486135T1 (de) * 2007-07-20 2010-11-15 Univ Liege Kombination aus verfahren zur sequentiellen messung (1.) der enzymatisch aktiven fraktion und (2.) der gesamtmenge eines enzyms
WO2009064970A1 (en) * 2007-11-14 2009-05-22 Medtronic, Inc. Genetic markers for scd or sca therapy selection
US20110143956A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Diagnostic Kits and Methods for SCD or SCA Therapy Selection
US20100056873A1 (en) * 2008-08-27 2010-03-04 Allen Paul G Health-related signaling via wearable items
US8130095B2 (en) 2008-08-27 2012-03-06 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8284046B2 (en) 2008-08-27 2012-10-09 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8094009B2 (en) 2008-08-27 2012-01-10 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8125331B2 (en) 2008-08-27 2012-02-28 The Invention Science Fund I, Llc Health-related signaling via wearable items
US20100081928A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological Facilitation systems and methods
US20100317006A1 (en) * 2009-05-12 2010-12-16 Medtronic, Inc. Sca risk stratification by predicting patient response to anti-arrhythmics
FI20095733A0 (fi) 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä
RU2548710C2 (ru) * 2009-09-17 2015-04-20 Ф.Хоффманн-Ля Рош Аг Мультимаркерная панель для гипертрофии левого желудочка
FI20115367A0 (fi) 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
US20150080738A1 (en) * 2011-08-16 2015-03-19 The General Hospital Corporation Apparatus, method, and computer-accessible medium for determining antigen immunoreactivity in tissue
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
RU2646490C1 (ru) * 2016-09-16 2018-03-05 Гюзелия Хатыбулловна Каюмова Способ прогнозирования летальности у пациентов с инфарктом миокарда
EP3662480A4 (en) 2017-08-04 2021-05-19 BillionToOne, Inc. TARGET-ASSOCIATED MOLECULES FOR CHARACTERIZATION IN CONNECTION WITH BIOLOGICAL TARGETS
US11519024B2 (en) * 2017-08-04 2022-12-06 Billiontoone, Inc. Homologous genomic regions for characterization associated with biological targets
KR102109850B1 (ko) * 2017-08-21 2020-05-13 한양대학교 산학협력단 염증의 유무 예측을 위한 바이오마커

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525641A (en) * 1894-09-04 Weather-strip
US5039521A (en) * 1989-01-11 1991-08-13 Hyal Pharmaceutical Corporation Immune cell proliferation inhibitors
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
AU5355094A (en) * 1992-10-14 1994-05-09 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
WO1994021686A1 (en) * 1993-03-19 1994-09-29 Northern Sydney Area Health Service Papp-a, its immunodetection and uses
ATE458499T1 (de) * 1995-06-07 2010-03-15 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
AU5596298A (en) 1996-12-09 1998-07-03 Cor Therapeutics, Inc. Integrin antagonists
PT1003501E (pt) 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
CA2367360C (en) 1999-03-15 2011-08-09 Michael Toft Overgaard Insulin-like growth factor binding protein-4 protease
US7115382B1 (en) * 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
JP4251617B2 (ja) 2003-03-10 2009-04-08 キヤノン株式会社 電子機器
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation

Also Published As

Publication number Publication date
AU2002241845B2 (en) 2006-11-09
US8323913B2 (en) 2012-12-04
US20020132278A1 (en) 2002-09-19
DE60232303D1 (de) 2009-06-25
JP4338972B2 (ja) 2009-10-07
US7939280B2 (en) 2011-05-10
US6699675B2 (en) 2004-03-02
JP2009198510A (ja) 2009-09-03
WO2002056015A1 (en) 2002-07-18
US20090197342A1 (en) 2009-08-06
EP1350109B1 (en) 2009-05-13
US20070065879A1 (en) 2007-03-22
JP2004531696A (ja) 2004-10-14
US20040197844A1 (en) 2004-10-07
ES2324767T3 (es) 2009-08-14
JP2010281833A (ja) 2010-12-16
US7723049B2 (en) 2010-05-25
CA2434512A1 (en) 2002-07-18
EP1350109A1 (en) 2003-10-08
US20060110773A1 (en) 2006-05-25
JP5226749B2 (ja) 2013-07-03
CA2434512C (en) 2010-05-11
ATE431551T1 (de) 2009-05-15
US20030003521A1 (en) 2003-01-02
EP1350109A4 (en) 2004-08-18
US6500630B2 (en) 2002-12-31
PT1350109E (pt) 2009-06-30
US20050136498A1 (en) 2005-06-23
US20100285510A1 (en) 2010-11-11
US20110212024A1 (en) 2011-09-01
EP2081026A1 (en) 2009-07-22
JP4610660B2 (ja) 2011-01-12

Similar Documents

Publication Publication Date Title
DK1350109T3 (da) Markör for betændelsestilstande
NO2020005I1 (no) ustekinumab. Forlenget SPC
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
DE60233731D1 (de) Werkstück-positioniervorrichtung
DE60216839D1 (de) Leistungsverstärker
ATE420640T1 (de) Fab-i-inhibitoren
DE50212025D1 (de) Lösungen organischer halbleiter
DE50211354D1 (de) Transportwagen
DE50113812D1 (de) Explosivstoffgetriebene RF-Strahlenquelle
ATE502118T1 (de) Amplifizierungsverfahren
DE60229592D1 (de) Radlager
FR2845917B1 (fr) Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
DE50113261D1 (de) Linearwälzlager
DE60103725D1 (de) Laserquelle
NO20006447D0 (no) Bölgeleder-laserkilde
DE60229669D1 (de) X-2 inhibitoren
ATE535775T1 (de) Präzisionsdendrometer
DE60216461D1 (de) Stabilitätsverbesserter multistufe-leistungsverstärker
DE60136750D1 (de) Werkstückträger
DE60220872D1 (de) Linearlagerführung
BRPI0307722A2 (pt) microorganismo envolvido
DE50209630D1 (de) Drehmaschine
DE50201269D1 (de) Radiallager
FR2831844B3 (fr) Piece usinee par transformation